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gained. Sensitivity analyses show that vaccine efﬁ cacy and whether vaccine is life-long
protective are the most inﬂ uential parameters impacting model outcomes. ICER
changed to 71.11% if the efﬁ cacy is down to 70%, 32.60% if the efﬁ cacy is 100%; 
and 200.04% if the vaccine provides only 10 year protection. CONCLUSIONS: These
results show that HPV vaccine is cost-effective compared to screening alone. Further 
studies should be done to establish more precise model parameters, such as vaccine
efﬁ cacy, duration, adverse event rates and cost for adverse events.
PIN18
THE ESTABLISHMENT OF A COST-EFFECTIVE ANTIBIOTIC TREATMENT 
OF INFECTIVE ENDOCARDITIS AND MRSA BACTEREMIA IN MEXICAN 
PUBLIC HEALTH CARE SYSTEM
Baca-Muro VI1, Soria–Cedillo IF2, Jirash J3, Olvera K3, De la Mora-Chávez T4, 
Garcia-Contreras F4
1Research Consulting, Puebla, Puebla, Mexico, 2Research Consulting, Hacienda Ojo de Agua, 
State of Mexico, Mexico, 3Novartis Farmaceutica Mexico, Mexico City, Mexico City, Mexico, 
4Instituto Mexicano del Seguro Social, Mexico City, Mexico
OBJECTIVES: To determine whether the use of i.v. Daptomycin or i.v. Vancomycin
is the most cost-effective alternative for the treatment of infective endocarditis in public
health care institutions in Mexico METHODS: A cost-effectiveness study was per-
formed considering an institutional perspective and comparing the use of the evaluated 
alternatives as ﬁ rst-line antibiotic therapy. A systematic review was performed in order
to collect data about clinical success, length of stay at hospital services and adverse
events due to the use of either i.v. Daptomycin or i.v. Vancomycin. The use of resources 
matrix considered the selected antibiotic therapy, concomitant medication, length of 
stay at hospital services, and a second-line antibiotic therapy in case of failure. A 
decision tree with Bayesian approach was designed to simulate the use of resources.
Patient’s outcomes were supposed to be clinical success (in either short hospital stay 
or long hospital stay) and therapeutic failure which can be caused by death or lack
of efﬁ cacy of the antibiotic. Results were evaluated with incremental analysis and 
one-way sensitivity analysis of the most uncertain variables were also conducted. 
RESULTS: The use of i.v. Daptomycin results in the lowest total cost (DAP: $7,847.00 
USD; VAN:$7,990.00 USD) and the lowest cost per clinical success (CS) (DAP:
$17,754.00 USD/CS; VAN:$23,083.00 USD/CS) compared with i.v. Vancomycin. The 
sensitivity analysis varying clinical success rates of every evaluated alternative showed 
robustness of base study. CONCLUSIONS: Daptomycin is the most cost-effective
alternative in the treatment of Infective Endocarditis and MRSA Bacteremia when 
used as ﬁ rst-line antibiotic therapy, since its use reduces the length of hospital stay 
reducing expenses of public health system budget in Mexico. The use of Daptomycin
can be considered as safer when compared to use Vancomycin, because it has been 
reported less frequently event adverse in long term treatments.
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OBJECTIVES: Polymyxin B-immobilized hemoperfusion cartage (PMX) is a medical
device for the treatment of severe sepsis by adsorbing and eliminating plasma endo-
toxin. The objective of this study is to assess the clinical effectiveness and cost-
effectiveness of PMX vs. conventional therapy in treating patients with severe sepsis. 
METHODS: For a systematic review, we searched OVID, EMBASE and Cochrane 
central register of controlled trial (CENTRAL). Inclusion criteria of clinical trials were
RCTs on ‘sepsis’, ‘severe sepsis’ and ‘septic shock’ patients. We included those studies
that reported at least one of the four speciﬁ ed outcomes: mortality, plasma endotoxin
level, days of ICU stay and blood pressure. Relevant outcomes were synthesized using 
RevMan 5.0. The average medical cost of sepsis was estimated from a national health 
insurance (NHI) claims database and the PMX related cost was calculated from the 
fee schedule of NHI. For economic evaluation, we assessed incremental cost effective-
ness ratio (ICER) of PMX compared with conventional therapy. The assessment was
performed from a purchaser’s perspective. RESULTS: A total of 11 RCTs were identi-
ﬁ ed with pooled sample size of 802; 477 in PMX and 325 in conventional therapy 
group. Meta-analysis results showed that PMX therapy had signiﬁ cantly lower mortal-
ity risk. The 28-day mortality rate of PMX group and conventional therapy group
were 35.4% and 70.4% respectively with risk ratio of 0.51 (95% CI, 0.43–0.59). The
medical cost for sepsis turned out 3,536,000 KRW per patient, which is common in 
PMX and conventional treatment. The additional cost related to PMX treatment was 
estimated to be KRW5,496,984 KRW per patient. Applying this mortality outcome
and cost data, we produced an ICER of KRW15,705,669 per life gained. CONCLU-
SIONS: Compared with conventional therapy alone, PMX therapy with conventional
therapy for the treatment of severe sepsis was found clinically superior and cost-
effective as well.
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OBJECTIVES: Streptococcus pneumoniae infections in adults are associated with
substantial morbidity, mortality, and costs. The objective of this study was to provide 
an analysis of the conclusions and assumptions of published studies on the cost-
effectiveness of pneumococcal polysaccharide vaccination (PPV-23 (23 serotypes)) in
adults. METHODS: A search of recent literature (1997–2008) was conducted to 
identify cost-effectiveness studies pertaining to the use of PPV for the prevention of 
invasive pneumococcal disease (IPD) in adults. A structured review of the impact of 
model assumptions on cost-effectiveness ratios was undertaken. Cost per life year
gained (LYG) or quality adjusted life year (QALY) were reported in 2007 US dollars. 
RESULTS: The literature search identiﬁ ed 31 studies, 19 of which reported some cost
data but did not include cost–effectiveness data for PPV-23 vaccination. All but one 
of the remaining twelve studies compared PPV-23 vaccination with no vaccination, 
and these were included in this analysis. Vaccination of over 65 year olds with PPV-23 
for the prevention of IPD was found to be cost-effective with incremental cost effective-
ness ratios ranging from 2007 $9,810 to $26,160 per LYG and from $9.08 (cost-
saving) to $53,955 per QALY. Review of model parameters revealed that the results 
of these studies have to be considered in the light of limitations of available data on 
vaccine effectiveness, disease incidence, and case-fatality ratios. CONCLUSIONS: All 
the reviewed studies reported that PPV-23 is a cost-effective, and in some cases a
cost-saving, vaccination strategy for the prevention of IPD in the elderly. Further eco-
nomic evaluation of PPV-23 may be warranted based on the availability of new data 
on vaccine efﬁ cacy, IPD incidence and case fatality in the adult population in the
post-PCV-7 era.
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OBJECTIVES: To investigate how the cost-effectiveness of preventing or treating 
HIV/AIDS varies by a series of potentially relevant external factors. METHODS:
We reviewed the cost-effectiveness evidence for HIV/AIDS prevention and treat-
ment in the Cost-Effectiveness (CEA) Analysis Registry at Tufts Medical Center
(www.cearegistry.org) from 2002–06, and then constructed efﬁ cient frontier curves 
(EF curve) in terms of incremental cost per QALY ratios based on extracted evidence 
using methods introduced by Institute for Quality and Efﬁ ciency in Health Care
(IQWiG), Germany. All articles that report cost-effectiveness as USD/QALYs were
selected, including information on the following factors: payer perspective; prevention 
stage; intervention type, and country of study. We excluded articles with time horizon
30 years and those without discounting. RESULTS: Of 237 eligible articles in the 
CEA Registry, we extracted 11 HIV/AIDS-related articles, which included 84 individ-
ual cost-effectiveness (CE) ratios. Plotted EF curves were visually distinct, depending
on the prevention type, with primary prevention interventions being most efﬁ cient.
With respect to country, the EF curve for the U.S. and South Africa were separate,
with the curve for South Africa lying near the vertical axis, reﬂ ecting low cost per
QALY ratios for interventions studied. Subgrouping by payer perspective (societal or 
health care payer) and intervention type (pharmaceutical, education, and screening)
did not affect the separation of the lines. CONCLUSIONS: The CE ratio clustering 
in HIV/AIDS was found on the C-E plane, which suggested separate EF curves should
be considered by stratifying by prevention stage and country. These results may differ
for other diseases, but this analysis shows that stratiﬁ ed EF analysis could help to
develop a deeper appreciation of cost-effectiveness beyond crude cost per QALY ratios
without stratiﬁ cation.
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OBJECTIVES: Vaccination of elderly and at-risk population against Streptococcus 
pneumonia is recommended and partially reimbursed in Turkey due to the substantial 
medical and economic burden. However, only ^2% of these populations were vacci-
nated in 2007. A three-step economic analysis was designed to measure the burden 
of pneumococcal infections (pneumonia and bacteremia) from a public payer perspec-
tive in elderly (60 years) and at-risk adults (18–59 years), and to evaluate the beneﬁ ts 
of implementing a vaccination program. METHODS: Firstly, we evaluated the cost 
of pneumonia and bacteremia in retrospective and prospective studies in public 
hospital services in Ankara. Secondly, a static model was used to evaluate cost-
effectiveness of vaccination in the two targeted populations using demographic and
epidemiological data obtained from Turkish sources or, when unavailable, from inter-
national literature. A stochastic Monte Carlo simulation estimated the incremental 
cost-effectiveness ratio in Euros (€) per life year gained (LYG), assuming that vaccina-
tion protected for 5 years with 50–70% effectiveness against pneumococcal bacteremia 
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and 15–45% against pneumococcal pneumonia. Finally, the budget-impact associated
with the percentage of people vaccinated was analyzed. RESULTS: The mean effective-
ness of pneumococcal vaccination in the Turkish population was 31,611 LYG (95% 
CI: 30,756-32,467) in the elderly and 13,353 LYG (95% CI: 12,989–13,716) in at-risk 
adults. The vaccination program was found to be cost saving with mean incremental
savings of €76 million (95% CI: 170 to 122) in the elderly and €35 million (95% CI: 
74 to 59) in at risk adults. Budget impact analysis showed that the total cost saved
increased with increasing vaccine coverage rate. CONCLUSIONS: This analysis sug-
gests that pneumococcal vaccination of elderly and at-risk adults is associated with a 
positive return on investment from a public payer perspective and supports the con-
tinued recommendation of pneumococcal vaccines, as well as their full funding.
PIN23
APPLYING THE EFFICIENCY FRONTIER IN PHARMACEUTICAL
POLICY MAKING. A CASE STUDY IN TREATMENT RESISTANT HIV/AIDS
PATIENTS IN THE GERMAN SETTING
Annemans L1, Hill A2, Smets E3, Martin SC3
1University of Ghent, Brussels University, Ghent, Belgium, 2HIV Solutions, London, UK, 
3Johnson & Johnson Pharmaceutical Services LLC, Mechelen, Belgium
OBJECTIVES: Recently, the German IQWIG has proposed the efﬁ ciency frontier 
approach to support decisions regarding reimbursed price levels, and published recom-
mended methods in 2008. Treatment regimens appearing on the efﬁ ciency frontier are
considered the most economically efﬁ cient. Our aim was to apply these methods in 
an economic evaluation of pharmaceutical options in treatment-experienced HIV/
AIDS patients. METHODS: We identiﬁ ed 10 published randomized controlled trials 
for the target population (POWER 1&2, RESIST 1&2, MOTIVATE 1&2, DUET
1&2, BENCHMRK 1&2), of which the following information was extracted for all 
arms: baseline characteristics; % of patients with a viral load 50 copies/mL at week
48 (response rates); enfuvirtide (ENF) use as co-medication and its impact on response; 
and the use of antiretroviral therapies during the studies. Unit drug costs were obtained 
from Rote Liste. A one year time horizon was chosen. The results of all treatment
arms (average and  or – ENF) were plotted on a coordinate system with annual drug
costs per patient on the horizontal axis and response rates on the vertical axis, the 
latter after adjustment for baseline characteristics using logistic regression on the
pooled raw data of the DUET trials. RESULTS: Twenty-six cost-efﬁ cacy points were 
created representing all compared strategies. Drug costs per year per patient varied 
between €22,186 and €61,715. Response rates varied between 8.4% and 68.7%. All 
interventions appearing on the frontier were combinations including etravirine. The 
last line segment of the frontier had a slope of €1354 per extra percentage response. 
CONCLUSIONS: Constructing an efﬁ ciency frontier plot was feasible in this indica-
tion. However, detailed baseline characteristics and logistic regression were required
for adjustment. Regimens containing etravirine appear to be economically efﬁ cient.
Longer term evaluation including all health care costs could add valuable information, 
but would require many assumptions given the limited available data for the 26 com-
pared strategies.
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OBJECTIVES: Pneumococcal-infected diseases (PID) including pneumonia and bac-
teremia, accounts for 22.1% of mortality among the elderly aged over 65 in Taiwan. 
They are also the major causes of hospital admission for the elderly. Although proved
effective in preventing elderly PID, the cost and effectiveness of pneumococcal vaccina-
tion (PV) has not been fully acknowledged in Taiwan. This study aimed to apply an
economic analysis of PV in preventing elderly hospitalization due to PID. METHODS:
In payer’s perspective, we conducted a ﬁ ve-year cost-minimization analysis for the PV
in preventing elderly PID hospitalization. The efﬁ cacy data of PV was extracted from 
the related results of clinical trials or systematic reviews, while the epidemiologic and
cost data of elderly PID hospitalization were obtained from the reimbursement data-
base of National Health Insurance (NHI) of Taiwan in 2005. RESULTS: The elderly 
accounts for 33.3% of the PID hospitalization events in one year. The mean hospital-
ization days and mean cost for the elderly were 17.75 o 13.78 days and 111,112.7 o
137,596 national Taiwan dollars (NTD), respectively, which were the longest and the 
most expensive among all age groups. PV was estimated to save the Bureau of National 
Health Insurance about 4,442 and 9,574,953,100 NTD per year for a single and all 
elderly q 65, respectively. Even with the progressively decreased efﬁ cacy, PV is still a 
cost-saving approach for the elderly. CONCLUSIONS: Pneumococcal vaccination is 
cost-saving. Local cohort and pragmatic studies are needed for long-term follow up 
and cost-effectiveness analysis.
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OBJECTIVES: This study conducted the cost minimization analysis (CMA) of 
Posaconazole compared with currently licensed antifungal agents including Voricon-
azole (IV and oral), Caspofungin, and L-AMB in the treatment of conﬁ rmed infection 
of invasive aspergillosis with refractory disease in Korea. METHODS: Through a 
systematic review of preceding literature, we ﬁ rstly ﬁ gure out the factors that deter-
mine clinical success and clinical failure for each of the comparators and secondly
investigate whether Posaconazole decreases infectious morbidity and mortality of the 
patients from RCTs with various conditions. Without clinical or observational dataset 
of Posaconazole and other comparators of the treatment for Korean patients, this 
study indirectly adopted the determinants and probabilities from the clinical results
in all languages to decision tree model for antifungal treatment to estimate the clinical
outcomes, and conducted the probabilistic sensitivity analysis and economic analysis. 
This study also estimated the direct costs associated with invasive aspergillosis treat-
ment. RESULTS: For the antifungal treatment, the study showed that Posaconazole 
incurs smaller drug costs than Voriconazole depending upon the almost similar effec-
tiveness between the two AF agents. Based on the desired drug price of Posaconazole
(€61.90/400mg) and average KRW-Euro exchange rate in 2008, the result showed that 
incremental cost of KRW6,934,591 (€4,387.30) would be saved compared with the 
expected drug cost of Voriconazole, Caspofungin, and L-AMB based upon their
market shares. CONCLUSIONS: Probabilistic analysis on net monetary beneﬁ t
showed that invasive aspergillosis treatment with Posaconazole is cost-saving method 
in Korea compared to Voriconazole and other licensed antifungal agents.
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OBJECTIVES: Irrational antibiotic usage is still common in Turkey; and antibiotics 
are still the most commonly prescribed drugs in Turkey. The aim of this study was to 
evaluate the effects of generic drug usage in inpatient clinics in Turkey, compared to 
brand names. METHODS: Data was collected from the inpatient clinic of the Infec-
tious Disease Service of a University Hospital, in 2007. A total of 92 patients were
treated during this period, and 73% of them received antibiotics. The name of the
antibiotic, dosage and the duration of use were recorded by the researcher from patient
records. The price of the antibiotics were extracted from the Ministry of Health’s
ofﬁ cial price list. The cost of the bio-equivalent and the cheapest generic drugs were 
compared with the original drugs. RESULTS: During 2007, the cost of the antibiotics
used at the Infectious Disease inpatient clinic was $39,792.6, compared to the cheapest 
generics, which would have been $38,396.3. In this clinic, $20.8 per patient more was 
paid for the brand name antibiotics each month. If the 2000–2200 patients being
treated with antibiotics in this hospital per year are considered, an average of 
$47,484,980.1 per year is being paid for brand name antibiotics. CONCLUSIONS:
Considering antibiotics are the most commonly used medication in Turkey (17% of 
total drug usage), it can easily be understood how the use of Brand Name drugs rather 
than Generics would lead to a vast economic burden. This shows the importance of 
promoting the use of generic antibiotics and the need for cost-minimalization 
analysis.
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OBJECTIVES: A 3-round hepatitis-B immunization campaign covering 1989-born
adolescents was implemented in 2007 in Iran. This study was conducted for cost esti-
mation and analysis of this campaign. METHODS: This study was conducted apply-
ing health system perspective. The cost variables considered were recurrent costs, 
personnel costs, publicity costs, transportation costs and overhead costs. As the cam-
paign was implemented using health system facilities, there is no marginal costs for
capital items such as building and refrigerator. We provided the required data to esti-
mate recurrent costs, national-level supervision and publicity from existing data and
interview with experts. To estimate costs of vaccine administration, provincial supervi-
sion and outreach, we provided data from some of the provinces, then expanded the
results to the country. We used WHO recommended proportions to estimate trans-
portation and overhead costs. We used administrative data to estimate vaccination 
coverage. RESULTS: At the end of the third round, 70.0% of target population 
received full doses, 74.5% received at least 2 doses and 78.3% received at least 1 dose 
of vaccine. Total cost of the campaign was estimated as $8.991 million including 24%
for recurrent, 42% for personnel, 31% for transportation, 0.1% for publicity and 3% 
for overhead. Total cost was estimated as $2.3 per-dose-administered. Sensitivity 
analysis indicated that increasing campaign coverage upto 90% and using under 20 
years old vaccine dosage will decrease the cost to $1.9 per-dose-administered. Decreas-
ing campaign coverage and using above 20 years old vaccine dosage will increase the
cost to $2.5. Considering vaccine immunogenicity based on Iranian studies, the cost 
was estimated $7.1–7.2 per-person-seroprotected. CONCLUSIONS: The costs in this 
campaign are much lower than what in similar programs in developed countries.
Acceptable campaign coverage and lower health service cost in Iran can be responsible.
More attention is needed to publicity costs in further campaigns.
